To test whether EZH2 affects the sensitivity of LUAD cells to EGFR-TKIs, we knocked down EZH2 expression in lung cancer cells using siRNA and subjected the cells to the CCK8 assay after exposure to different concentrations of gefitinib for 24–48 h. The gene discussed is EZH2; the disease is lung carcinoma.